Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05247866 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
A Phase 4 study of Eosinophilic Esophagitis, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05247866: Completed Phase 4 study of Eosinophilic Esophagitis, sponsored by Children's Hospital of Philadelphia.
NCT05247866 is a Phase 4 study of Eosinophilic Esophagitis that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 21 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05247866, a Phase 4 study of Eosinophilic Esophagitis, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation. Current therapies include diet and the off label use of medications including proton pump inhibitors, topical steroids or biologics. Food elimination creates a decrease quality of life in many children. The goal of the study is to examine a T2 inhibitor (dupilumab) can allow successful reintroduction of allergic EoE foods into the diet. This is a single site study, enrolling subjects 6 to 25 years of age.
Primary Outcome
Eosinophils per high power field on esophageal biopsy
Conditions Studied
Interventions
- DRUG Dupilumab
- DIETARY_SUPPLEMENT Eosinophilic Esophagitis (EoE) food introduction-1st
- DIETARY_SUPPLEMENT Eosinophilic Esophagitis (E0E) food introduction-2nd
- DIETARY_SUPPLEMENT Eosinophilic Esophagitis (EoE) Food introduction-3rd dose
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2025-01-21 |
| Phase | Phase 4 |
What the finished NCT05247866 record still lists
NCT05247866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 4 interventions - of which Dupilumab is the first listed.
NCT05247866 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05247866 about?
NCT05247866 is a clinical study titled "Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis". Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation. Current therapies include diet and the off label use of medications including proton pump inhibitors, topical steroids or biologics. Food elimination creates a d...
What is the current status of trial NCT05247866?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2022-06-16. Estimated completion is 2025-01-21.
What conditions does trial NCT05247866 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT05247866?
The interventions under investigation include: Dupilumab (DRUG), Eosinophilic Esophagitis (EoE) food introduction-1st (DIETARY_SUPPLEMENT), Eosinophilic Esophagitis (E0E) food introduction-2nd (DIETARY_SUPPLEMENT), Eosinophilic Esophagitis (EoE) Food introduction-3rd dose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05247866?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05247866 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05247866's enrollment target sits among peer trials
21 38th of 44 higher than 6 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
ACTIVE NOT RECRUITING · Phase 4
-
Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis
COMPLETED · Phase 4
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
RECRUITING
-
Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study
RECRUITING
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
A Registry for the Food Allergy Community
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI